Structure-based design of novel, urea-containing FKBP12 inhibitors

Journal of Medicinal Chemistry

Volumn 39, Issue 9, 1996, Pages 1872-1884

  Dragovich, Peter S ^a   Barker, John E ^a   French, Judy ^a   Imbacuan, Michael ^a   Kalish, Vincent J ^a   Kissinger, Charles R ^a   Knighton, Daniel R ^a   Lewis, Cristina T ^a   Moomaw, Ellen W ^a   Parge, Hans E ^a   Pelletier, Laura A K ^a   Prins, Thomas J ^a   Showalter, Richard E ^a   Tatlock, John H ^a   Tucker, Kathleen D ^a   Villafranca, J Ernest ^a  

^a AGOURON PHARMACEUTICALS INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYCLOSPORIN A; IMMUNOPHILIN; IMMUNOSUPPRESSIVE AGENT; PROTEIN INHIBITOR; RAPAMYCIN; TACROLIMUS; TSUKUBAENOLIDE BINDING PROTEIN 12; TSUKUBAENOLIDE BINDING PROTEIN 12 INHIBITOR; UNCLASSIFIED DRUG; UREA;

COMPLEX FORMATION; CRYSTAL STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; INHIBITION KINETICS; REVIEW; STRUCTURE ACTIVITY RELATION;

AMINO ACID ISOMERASES; AMINO ACID SEQUENCE; CARRIER PROTEINS; CRYSTALLOGRAPHY, X-RAY; DNA-BINDING PROTEINS; DRUG DESIGN; HEAT-SHOCK PROTEINS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MOLECULAR SEQUENCE DATA; PEPTIDYLPROLYL ISOMERASE; STRUCTURE-ACTIVITY RELATIONSHIP; TACROLIMUS; TACROLIMUS BINDING PROTEINS; UREA;

EID: 15844367449     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm950798a     Document Type: Review

References (83)

1. Tanaka, H.; Kuroda, A.; Marusawa, H.; Hatanaka, H.; Kino, T.; Goto, T.; Hashimoto, M.; Taga, T. Structure of FK506: A Novel Immunosuppressant Isolated from Streptomyces. J. Am. Chem. Soc. 1987, 109, 5031-5033.
2. For recent reviews on this class of immunosuppressants, see: (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. The Cell Cycle, Signal Transduction, and Immunophilin-Ligand Complexes. Acc. Chem. Res. 1993, 26, 412-420. (b) Armistead, D. M.; Harding, M W. Immunophilins and Immunouppressive Drug Action. Annu. Rep Med. Chem. 1993, 28, 207-215. (c) Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; Schultz, L. W.; Clardy, J.; Schreiber, S. L. Synthesis, Structure and Mechanism in Immunophilin Research. Synlett 1994, 381-392. (d) Wiederrecht, G.; Etzkorn, F. The Immunophilins. Perspect. Drug Discovery Des. 1994, 2, 57-84. (e) O'Keefe, S. J.; O'Neill, E. A. Cyclosporin A and FK506: Immunosuppression, Inhibition of Transcription and the Role of Calcineurin. Perspect. Drug Discovery Des. 1994, 2, 85-102.
3. For recent reviews on this class of immunosuppressants, see: (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. The Cell Cycle, Signal Transduction, and Immunophilin-Ligand Complexes. Acc. Chem. Res. 1993, 26, 412-420. (b) Armistead, D. M.; Harding, M W. Immunophilins and Immunouppressive Drug Action. Annu. Rep Med. Chem. 1993, 28, 207-215. (c) Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; Schultz, L. W.; Clardy, J.; Schreiber, S. L. Synthesis, Structure and Mechanism in Immunophilin Research. Synlett 1994, 381-392. (d) Wiederrecht, G.; Etzkorn, F. The Immunophilins. Perspect. Drug Discovery Des. 1994, 2, 57-84. (e) O'Keefe, S. J.; O'Neill, E. A. Cyclosporin A and FK506: Immunosuppression, Inhibition of Transcription and the Role of Calcineurin. Perspect. Drug Discovery Des. 1994, 2, 85-102.
4. For recent reviews on this class of immunosuppressants, see: (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. The Cell Cycle, Signal Transduction, and Immunophilin-Ligand Complexes. Acc. Chem. Res. 1993, 26, 412-420. (b) Armistead, D. M.; Harding, M W. Immunophilins and Immunouppressive Drug Action. Annu. Rep Med. Chem. 1993, 28, 207-215. (c) Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; Schultz, L. W.; Clardy, J.; Schreiber, S. L. Synthesis, Structure and Mechanism in Immunophilin Research. Synlett 1994, 381-392. (d) Wiederrecht, G.; Etzkorn, F. The Immunophilins. Perspect. Drug Discovery Des. 1994, 2, 57-84. (e) O'Keefe, S. J.; O'Neill, E. A. Cyclosporin A and FK506: Immunosuppression, Inhibition of Transcription and the Role of Calcineurin. Perspect. Drug Discovery Des. 1994, 2, 85-102.
5. For recent reviews on this class of immunosuppressants, see: (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. The Cell Cycle, Signal Transduction, and Immunophilin-Ligand Complexes. Acc. Chem. Res. 1993, 26, 412-420. (b) Armistead, D. M.; Harding, M W. Immunophilins and Immunouppressive Drug Action. Annu. Rep Med. Chem. 1993, 28, 207-215. (c) Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; Schultz, L. W.; Clardy, J.; Schreiber, S. L. Synthesis, Structure and Mechanism in Immunophilin Research. Synlett 1994, 381-392. (d) Wiederrecht, G.; Etzkorn, F. The Immunophilins. Perspect. Drug Discovery Des. 1994, 2, 57-84. (e) O'Keefe, S. J.; O'Neill, E. A. Cyclosporin A and FK506: Immunosuppression, Inhibition of Transcription and the Role of Calcineurin. Perspect. Drug Discovery Des. 1994, 2, 85-102.
6. For recent reviews on this class of immunosuppressants, see: (a) Schreiber, S. L.; Albers, M. W.; Brown, E. J. The Cell Cycle, Signal Transduction, and Immunophilin-Ligand Complexes. Acc. Chem. Res. 1993, 26, 412-420. (b) Armistead, D. M.; Harding, M W. Immunophilins and Immunouppressive Drug Action. Annu. Rep Med. Chem. 1993, 28, 207-215. (c) Belshaw, P. J.; Meyer, S. D.; Johnson, D. D.; Romo, D.; Ikeda, Y.; Andrus, M.; Alberg, D. G.; Schultz, L. W.; Clardy, J.; Schreiber, S. L. Synthesis, Structure and Mechanism in Immunophilin Research. Synlett 1994, 381-392. (d) Wiederrecht, G.; Etzkorn, F. The Immunophilins. Perspect. Drug Discovery Des. 1994, 2, 57-84. (e) O'Keefe, S. J.; O'Neill, E. A. Cyclosporin A and FK506: Immunosuppression, Inhibition of Transcription and the Role of Calcineurin. Perspect Drug Discovery Des. 1994, 2, 85-102.
7. (a) Siekierka, J. J., Hung, S. H. Y.; Poe, M.; Lin, C. S.; Sigal, N. H A Cytosolic-Binding Protein for the Immunosuppressant FK506 has Isomerase Activity but is Distinct from Cyclophilin. Nature 1989, 341, 755-757.
8. (b) Harding, M. W.; Galat, A.; Uehling, D. E.; Schreiber, S. L. A Receptor for the Immunosuppressant FK506 is a Cis-Trans Peptidyl-Prolyl Isomerase. Nature 1989, 341, 758-760
9. (c) Siekierka, J. J.; Wiederrecht, G.; Greulich, H.; Boulton, D; Hung, S. H. Y.; Cryan, J.; Hodges, P. J.; Sigal, N. H. The Cytosolic-Binding Protein for the Immunosuppressant FK506 is Both a Ubiquitous and Highly Conserved Peptidyl-Prolyl Cis-Trans Isomerase. J. Biol. Chem. 1990, 265, 21011-21015.
10. Additional members of a group of proteins which bind FK506 have been identified and collectively named FKBPs. The 12 kDa protein originally termed FKBP is currently referred to as FKBP12. For the characterization of other (higher molecular weight) members of this family of proteins, see: Baughman, G.; Wiederrecht, G. J.; Campbell, N. F.; Martin, M. M.; Bourgeois, S. FKBP51, a Novel T-Cell Specific Immunophilin Capable of Calcineurin Inhibition. Mol. Cell. Biol. 1995, 15, 4395-4402 and references therein. See also: Fischer, G. Peptidyl-Prolyl cis/trans Isomerases and Their Effectors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1415-1436.
11. Additional members of a group of proteins which bind FK506 have been identified and collectively named FKBPs. The 12 kDa protein originally termed FKBP is currently referred to as FKBP12. For the characterization of other (higher molecular weight) members of this family of proteins, see: Baughman, G.; Wiederrecht, G. J.; Campbell, N. F.; Martin, M. M.; Bourgeois, S. FKBP51, a Novel T-Cell Specific Immunophilin Capable of Calcineurin Inhibition. Mol. Cell. Biol. 1995, 15, 4395-4402 and references therein. See also: Fischer, G. Peptidyl-Prolyl cis/trans Isomerases and Their Effectors. Angew. Chem., Int. Ed. Engl. 1994, 33, 1415-1436.
12. (a) Rosen, M. K.; Standaert, R. F.; Galat, A.; Nakatsuka, M.; Schreiber, S. L. Inhibition of FKBP Rotamase Activity by Immunosuppressant FK506: Twisted Amide Surrogate. Science 1990, 248, 863-866.
13. (b) Albers, M. W.; Walsh, C. T.; Schreiber, S. L. Substrate Specificity for the Human Rotamase FKBP: A View of FK506 and Rapamycin as Leucine-(Twisted Amide)-Proline Mimics. J. Org. Chem. 1990, 55, 4984-4986.
14. Rüegger, A.; Kuhn, M.; Lichti, H.; Loosli, H.-R.; Huguenin, R.; Quiquerez, C.; von Wartburg, A. Cyclosporin A, a Peptide Metabolite from Trichoderma polysporum (LINK ex PERS.) Rifai, with a Remarkable Immunosuppressive Activity. Helv. Chim. Acta 1976, 59, 1075-1092.
15. (a) Takahashi, N.; Hayano, T.; Suzuki, M. Peptidyl-Prolyl cis-trans Isomerase is the Cyclosporin A-Binding Protein Cyclophilin. Nature 1989, 337, 473-475.
16. (b) Fischer, G.; Wittman-Liebold, B.; Lang, K.; Kiefhaber, T.; Schmid, F. X. Cyclophilin and Peptidyl-Prolyl cis-trans Isomerase are Probably Identical Proteins. Nature 1989, 337, 476-478.
17. Findlay, J. A.; Radics, L. On the Chemistry and High Field Nuclear Magnetic Resonance Spectroscopy of Rapamycin. Can. J. Chem. 1980, 58, 579-590
18. (a) Bierer, B. E.; Mattila, P. S.; Standaert, R. F.; Herzenberg, L. A.; Burakoff, S. J.; Crabtree, G.; Schreiber, S. L. Two Distinct Signal Transmission Pathways in T Lymphocytes are Inhibited by Complexes Formed Between an Immunophilin and Either FK506 or Rapamycin. Proc. Natl. Acad. Sci U.S.A. 1990, 87, 9231-9235.
19. (b) Dumont, F J.; Melino, M. R.; Staruch, M J.; Koprak, S. L.; Fischer, P. A.; Sigal, N. H. The Immunosuppressive Macrolides FK506 and Rapamycin act as Reciprocal Antagonists in Murine T-cells. J. Immunol. 1990, 144, 1418-1424.
20. (a) Klee, C. B.; Draetta, G. F., Hubbard, M. J. Calcineurin. Adv. Enzymol. Relat. Areas Mol. Biol. 1988, 61, 149-200.
21. (b) Pallen, C; Sharma, R. K.; Wang, J. H. Regulation of Calcineurin: A Multifunctional Calmodulin-Stimulated Phosphatase. In Calcium Binding Proteins, Characterization and Properties, Vol. 1; Thompson, M. P., Ed.; CRC Press: Boca Raton, FL, 1988; pp 51-82.
22. (a) Liu, J.; Farmer, J. D., Jr.; Lane, W. S; Friedman, J.; Weissman, I.; Schreiber, S. L. Calcineurin is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes. Cell 1991, 66, 807-815.
23. (b) Fruman, D. A.; Klee, C B.; Bierer, B. E.; Burakoff, S. J. Calcineurin Phosphatase Activity in T Lymphocytes is Inhibited by FK506 and Cyclosporin A. Proc. Natl. Acad. Sci. U.S.A. 1992, 89, 3686-3690.
24. (a) Flanagan, W. M.; Corthésy, B.; Bram, R. J.; Crabtree, G. R. Nuclear Association of a T-Cell Transcription Factor Blocked by FK506 and Cyclosporin A. Nature 1991, 352, 803-807.
25. (b) Dumont, F. J.; Staruch, M. J.; Koprak, S. L, Melino, M. R.; Sigal, N. H. Distinct Mechanisms of Suppression of Murine T-Cell Activation by the Related Macrolides FK506 and Rapamycin. J. Immunol. 1990, 144, 251-258.
26. (c) Tocci, M. J.; Matkovich, D. A.; Collier, K. A.; Kwok, P ; Dumont, F.; Lin, S.; Degudicibus, S.; Siekierka, J. J; Chin, J.; Hutchinson, N. I. The Immunosuppressant FK506 Selectively Inhibits Expression of Early T-Cell Activation Genes. J. Immunol. 1989, 143, 718-726.
27. Bierer, B. E.; Somers, P. K.; Wandless, T. J.; Burakoff, S. J.; Schreiber, S. L. Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand. Science 1990, 350, 556-559.
28. Lepre, C. A.; Pearlman, D. A.; Cheng, J.-W., DeCenzo, M. T.; Livingston, D. J.; Moore, J. M. Solution Structure of FK506 Bound to the R42K, H87V Double Mutant of FKBP-12. Biochemistry 1994, 33, 13571-13580. See also: Meadows, R. P.; Nettesheim, D. G.; Xu, R. X; Olejniczak, E. T.; Petros, A. M.; Holzman, T. F.; Severin, J.; Gubbins, E.; Smith, H.; Fesik, S. W Three-Dimensional Structure of the FK506 Binding Protein/ Ascomycin Complex in Solution by Heteronuclear Three- and Four-Dimensional NMR. Biochemistry 1993, 32, 754-765.
29. Lepre, C. A.; Pearlman, D. A.; Cheng, J.-W., DeCenzo, M. T.; Livingston, D. J.; Moore, J. M. Solution Structure of FK506 Bound to the R42K, H87V Double Mutant of FKBP-12. Biochemistry 1994, 33, 13571-13580. See also: Meadows, R. P.; Nettesheim, D. G.; Xu, R. X; Olejniczak, E. T.; Petros, A. M.; Holzman, T. F.; Severin, J.; Gubbins, E.; Smith, H.; Fesik, S. W Three-Dimensional Structure of the FK506 Binding Protein/ Ascomycin Complex in Solution by Heteronuclear Three- and Four-Dimensional NMR. Biochemistry 1993, 32, 754-765.
30. (a) Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structure of FKBP-FK506, an Immunophilin-Immunosuppressant Complex. Science 1991, 252, 839-842.
31. (b) Van Duyne, G. D.; Standaert, R. F.; Karplus, P. A.; Schreiber, S. L.; Clardy, J. Atomic Structures of the Human Immunophilin FKBP-12 Complexes with FK506 and Rapamycin. J. Mol. Biol. 1993, 229, 105-124.
32. (c) Clardy, J. Structural Studies on FK506, Cyclosporin A and Their Immunophilin Complexes. Perspect. Drug Discovery Des. 1994, 2, 127-144.
33. (d) Wilson, K. P.; Yamashita, M. M.; Sintchak, M. D.; Rotstein, S. H.; Murcko, M. A.; Boger, J.; Thomson, J. A.; Fitzgibbon, M. J.; Black, J. R.; Navia, M, A. Comparative X-ray Structures of the Major Binding Protein for the Immunosuppressant FK506 (Tacrolimus) in Unligated Form and in Complex with FK506 and Rapamycin. Acta Crystallogr. 1995, D51, 511-521.
34. (a) Griffith, J. P.; Kim, J. L.; Kim, E. E.; Sintchak, M. D.; Thomson, J. A.; Fitzgibbon, M. J.; Fleming M. A.; Caron, P. R.; Hsiao, K.; Navia, M. A. X-ray Structure of Calcineurin Inhibited by the Immunophihn-Immunosuppressant FKBP12-FK506 Complex. Cell 1995, 82, 507-522.
35. (b) Kissinger, C. R.; Parge, H. E.; Knighton, D. R.; Lewis, C. T.; Pelletier, L. A.; Tempczyk, A.; Kalish, V. J.; Tucker, K. D.; Showalter, R. E.; Moomaw, E. W.; Gastinel, L. N.; Habuka, N.; Chen, X.; Maldonado, F.; Barker, J. E.; Bacquet, R.; Villafranca, J. E. Crystal Structures of Human Calcineurin and the Human FKBP12-FK506-Calcineurin Complex. Nature 1995, 378, 641-644.
36. For a discussion of the possible intricacies of Calcineurin inhibition by the FKBP12-FK506 complex, see refs 15d and 16a.
37. For an excellent review of FK506 structure-activity studies, see: Goulet, M. T.; Ruppreeht, K. M.; Sinclair, P. J.; Wyvratt, M. J.; Parsons, W. H. The Medicinal Chemistry of FK506. Perspect. Drug Discovery Des. 1994, 2, 145-162.
38. (a) Aldape, R. A.; Futer, O.; DeCenzo, M. T.; Jarrett, B. P.; Murcko, M. A.; Livingston, D. J. Charged Surface Residues of FKBP12 Participate in Formation of the FKBP12-FK506-Calcineurin Complex. J. Biol. Chem. 1992, 267, 16029-16032.
39. (b) Yang, D.; Rosen, M. K.; Schreiber, S. L. A Composite FKBP12-FK506 Surface That Contacts Calcineurin. J. Am. Chem. Soc. 1993, 115, 819-820.
40. (c) Futer, O.; DeCenzo, M. T.; Aldape, R. A.; Livingston, D. J. FK506 Binding Protein Mutational Analysis J. Biol. Chem. 1995, 270, 18935-18940.
41. (a) Armistead, D. A.; Boger, J. S.; Meyers, H. V.; Saunders, J. O.; Tung, R. D. Immunosuppressive Compounds. U.S. Patent 5 192 773, 1993.
42. (b) Holt, D. A.; Luengo, J. I.; Yamashita, D. S.; Oh, H.-J.; Konialian, A. L.; Yen, H.-K.; Rozamus, L. W.; Brandt, M.; Bossard, M. J.; Levy, M. A.; Eggleston, D. S.; Liang, J.; Schultz, L. W.; Stout, T. J.; Clardy, J. Design, Synthesis, and Kinetic Evaluation of High-Affinity FKBP Ligands and the X-ray Crystal Structures of Their Complexes with FKBP12. J. Am. Chem. Soc. 1993, 115, 9925-9938.
43. (c) Holt, D. A.; Konialian-Beck, A. L.; Oh, H.-J.; Yen, H.-K.; Rozamus, L. W.; Krog, A. J.; Erhard, K. F.; Ortiz, E.; Levy, M. A.; Brandt, M.; Bossard, M. J.; Luengo, J. I. Structure-Activity Studies of Synthetic FKBP Ligands as Peptidvl-Prolyl Isomerase Inhibitors. Bioorg. Med. Chem. Lett. 1994, 4, 315-320.
44. (d) Luengo, J. I.; Konialian-Beck, A.; Levy, M. A.; Brandt, M.; Eggleston, D. S.; Holt, D. A. Synthesis and Structure-Activity Relationships of Macrocyclic FKBP Ligands. Bioorg. Med. Chem. Lett. 1994, 4, 321-324.
45. (e) Yamashita, D. S.; Oh, H.-J.; Yen, H.-K.; Bossard, M. J.; Brandt, M.; Levy, M. A.; Newman-Tarr, T.; Badger, A.; Luengo, J. I.; Holt, D. A. Design, Synthesis and Evaluation of Dual Domain FKBP Ligands. Bioorg. Med. Chem. Lett. 1994, 4, 325-328.
46. (f) Wang, G. T.; Lane, B.; Fesik, S. W.; Petros, A.; Luly, J.; Krafft, G. A. Synthesis and FKBP Binding of Small Molecule Mimics of the Tricarbonyl Region of FK506. Bioorg. Med. Chem. Lett. 1994, 4, 1161-1166.
47. (g) Birkenshaw, T. N.; Caffrey, M. V.; Cladingboel, D. E.; Cooper, M. E.; Donald, D. K.; Furber, M.; Hardern, D. N.; Harrison, R. P.; Marriott, D. P.; Perry, M. W. D.; Stocks, M. J.; Teague, S. J.; Withnall, W. J. Synthetic FKBP12 Ligands. Design and Synthesis of Pyranose Replacements. Bioorg. Med. Chem. Lett. 1994, 4, 2501-2506.
48. (h) Caffrey, M. V.; Cladingboel, D. E.; Cooper, M. E.; Donald, D. K.; Furber, M.; Hardern, D. N.; Harrison, R. P.; Stocks, M. J.; Teague, S. J. Synthesis and Evaluation of Dual Domain Macrocyclic FKBP12 Ligands. Bioorg. Med. Chem. Lett. 1994, 4, 2507-2510.
49. (i) Armistead, D. M.; Badia, M. C.; Deininger, D. D; Duffy, J. P.; Saunders, J. O.; Tung, R. D.; Thomson, J. A.; DeCenzo, M. T.; Futer, O.; Livingston, D. J.; Murcko, M. A.; Yamashita, M. M.; Navia, M. A. Design, Synthesis and Structure of Non-macrocyclic Inhibitors of FKBP12, the Major Binding Protein for the Immunosuppressant FK506. Acta Crystallogr. 1995, D51, 522-528.
50. (j) Tatlock, J. H.; Kalish, V. J.; Parge, H. E.; Knighton, D. R.; Showalter, R. E.; Lewis, C. T.; French, J. V.; Villafranca, J. E. High-Affinity FKBP-12 Ligands Derived from (R)-(-)-Carvone. Synthesis and Evaluation of FK506 Pyranose Ring Replacements. Bioorg. Med. Chem. Lett. 1995, 5, 2489-2494.
51. (a) Hauske, J. R.; Dorff, P.; Julin, S.; DiBrino, J.; Spencer, R.; Williams, R. Design and Synthesis of Novel FKBP Inhibitors. J. Med. Chem. 1992, 35, 4284-4296.
52. (b) Andres, C. J.; Macdonald, T. L.; Ocain, T. D.; Longhi, D. Conformationally Defined Analogs of Prolylamides, trans-Prolyl Peptidomimetics. J. Org. Chem. 1993, 58, 6609-6613.
53. (c) Babine, R E.; Bleckman, T. M.; Kissinger, C. R.; Showalter, R.; Pelletier, L. A.; Lewis, C; Tucker, K.; Moomaw, E.; Parge, H. E.; Villafranca, J. E. Design, Synthesis and X-ray Crystallographic Studies of Novel FKBP-12 Ligands. Bioorg. Med. Chem. Lett. 1995, 5, 1719-1724.
54. (d) Reference 20c.
55. (a) Duffy, J. P. Novel Immunosuppressive Compounds. International Patent Application WO 92/21313, 1992.
56. (b) Reference 20c.
57. A non-macrocyclic molecule which associates with FKBP12 at the 0.20 μM level and displays Calcineurin inhibitory properties has been reported; see: Andrus, M. B.; Schreiber, S. L. Structure-Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin. J. Am. Chem. Soc. 1993, 115, 10420-10421. See also: Furber, M. FKBP12-Ligand-Calcineurin Interactions: Analogues of SBL506. J. Am. Chem. Soc. 1995, 117, 7267-7268.
58. A non-macrocyclic molecule which associates with FKBP12 at the 0.20 μM level and displays Calcineurin inhibitory properties has been reported; see: Andrus, M. B.; Schreiber, S. L. Structure-Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin. J. Am. Chem. Soc. 1993, 115, 10420-10421. See also: Furber, M. FKBP12-Ligand-Calcineurin Interactions: Analogues of SBL506. J. Am. Chem. Soc. 1995, 117, 7267-7268.
59. Greer, J.; Erickson, J. W.; Baldwin, J. J.; Varney, M. D. Application of the Three-Dimensional Structures of Protein Target Molecules in Structure-Based Drug Design. J. Med. Chem. 1994, 37, 1035-1054 and references therein.
60. Michnick, S. W.; Rosen, M. K.; Wandless, T. J.; Karplus, M.; Schreiber, S. L. Solution Structure of FKBP, a Rotamase Enzyme and Receptor for FK506 and Rapamycin. Science 1991, 252, 836-839.
61. 16a
62. (a) Wiley, R. A.; Rich, D. H. Peptidomimetics Derived From Natural Products. Med. Res. Rev. 1993, 13, 368-378.
63. (b) Petros, A. M.; Luly, J. R.; Liang, H.; Fesik, S. W. Conformation of an FK506 Analog in Aqueous Solution is Similar to the FKBP-Bound Conformation of FK506. J. Am. Chem. Soc. 1993, 115, 9920-9924.
64. Majer, P.; Randad, R. S. A Safe and Efficient Method for Preparation of N,N′-Unsymmetrically Disubstituted Ureas Utilizing Triphosgene. J. Org. Chem. 1994, 59, 1937-1938.
65. Kotani, R. Demjanov Rearrangement of 1-Methylcyclohexyl-methylamine. J. Org. Chem. 1965, 30, 350-354.
66. 2 Analogues Modified at the Prolyl Residue and Evaluation of Their Effects on the Receptor Binding Activity of the Central Dopamine Receptor Agonist, ADTN. J. Med. Chem. 1986, 29, 2104-2107.
67. Brown, H. C.; Krishnamurthy, S.; Stocky, T. P. Selective Reductions XIX. The Rapid Reaction of Carboxylic Acids with Borane-Tetrahydrofuran. A Remarkably Convenient Procedure for the Selective Conversion of Carboxylic Acids to the Corresponding Alcohols in the Presence of Other Functional Groups. J. Org. Chem. 1973, 38, 2786-2792.
68. The identity of the major acyclic urea isomer (cis or trans) in chloroform solution is currently unknown.
69. (1.3) Strain on the Stereochemical Course of N-Acyliminium Ion Cyclizations. J. Am. Chem. Soc. 1980, 102, 397-398. (b) Hart, D. J.; Kanai, K.-i. New Approach to Lythraceae Alkaloids: Total Synthesis of (±)-Vertaline. J. Org. Chem. 1982, 47, 1555-1560. (c) Hart, D. J.; Yang, T.-K. N-Acyliminium Ion Rearrangements: Generalities and Application to the Synthesis of Pyrrolizidine Alkaloids. J. Org. Chem. 1985, 50, 235-242.
70. (1.3) Strain on the Stereochemical Course of N-Acyliminium Ion Cyclizations. J. Am. Chem. Soc. 1980, 102, 397-398. (b) Hart, D. J.; Kanai, K.-i. New Approach to Lythraceae Alkaloids: Total Synthesis of (±)-Vertaline. J. Org. Chem. 1982, 47, 1555-1560. (c) Hart, D. J.; Yang, T.-K. N-Acyliminium Ion Rearrangements: Generalities and Application to the Synthesis of Pyrrolizidine Alkaloids. J. Org. Chem. 1985, 50, 235-242.
71. (1.3) Strain on the Stereochemical Course of N-Acyliminium Ion Cyclizations. J. Am. Chem. Soc. 1980, 102, 397-398. (b) Hart, D. J.; Kanai, K.-i. New Approach to Lythraceae Alkaloids: Total Synthesis of (±)-Vertaline. J. Org. Chem. 1982, 47, 1555-1560. (c) Hart, D. J.; Yang, T.-K. N-Acyliminium Ion Rearrangements: Generalities and Application to the Synthesis of Pyrrolizidine Alkaloids. J. Org. Chem. 1985, 50, 235-242.
72. Review: Speckamp, W. N.; Hiemstra, H. Intramolecular Reactions of N-Acyliminium Intermediates. Tetrahedron 1985, 41, 4367-4416.
73. The formation of diastereomeric alcohol and olefinic products in related N-acyliminium ion cyclization reactions has been reported. See refs 33b,c.
74. Robins, M. J.; Wilson, J. S.; Hansske, F. Nucleic Acid Related Compounds. 42. A General Procedure for the Efficient Deoxygenation of Secondary Alcohols. Regiospecific and Stereoselective Conversion of Ribonucleosides to 2′-Deoxynucleosides. J Am. Chem. Soc. 1983, 105, 4059-4060.
75. Schummer, D.; Höfle, G. Tris(trimethylsilyl)silane as a Reagent for the Radical Deoxygenation of Alcohols. Synlett 1990, 705-706.
76. Still, W. C.; Kahn, M.; Mitra, A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978, 43, 2923-2925.
77. Standaert, R. F.; Galat, A.; Verdine, G. L.; Schreiber, S. L. Molecular Cloning and Overexpression of the Human FK506-Binding Protein FKBP. Nature 1990, 346, 671-674.
78. X-PLOR, version 3.1. Brünger, A. T. X-PLOR v3.1 Manual. Yale University Press: New Haven, CT, 1992.
79. Quanta, version 4.1, is produced by BIOSYM/Molecular Simulations, Inc., 16 New England Executive Park, Burlington, MA 01803-5297.
80. McRee, D. E. A Visual Protein Crystallographic Software System for X11/Xview. J. Mol. Graph. 1992, 10, 44-47.
81. Kofron, J. L.; Kuzmic, P.; Kishore, V.; Colón-Bonilla, E; Rich, D. H. Determination of Kinetic Constants for Peptidyl Prolyl cis-trans Isomerases by an Improved Spectrophotometric Assay Biochemistry 1991, 30, 6127-6134.
82. (a) Harrison, R. K.; Stein, R. L. Substrate Specificities of the Peptidyl Prolyl cis-trans Isomerase Activities of Cyclophilin and FK-506 Binding Protein: Evidence for the Existence of a Family of Distinct Enzymes. Biochemistry 1990, 29, 3813-3816
83. (b) Reference 9a.